SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation

Biologicals

Volumn 33, Issue 2, 2005, Pages 95-99

  Rabenau, H F ^a   Biesert, L ^b   Schmidt, T ^b   Bauer, G ^a   Cinatl, J ^a   Doerr, H W ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Virus and Prion Validation Department   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DETERGENT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; SOLVENT;

ARTICLE; BLOOD TRANSFUSION; CYTOMEGALOVIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; PRIORITY JOURNAL; SARS CORONAVIRUS; VIREMIA; VIRUS; VIRUS ENVELOPE; VIRUS INACTIVATION; VIRUS TRANSMISSION;

DETERGENTS; HUMANS; IMMUNOGLOBULINS; SARS VIRUS; SOLVENTS; VIRUS INACTIVATION;

CUCUMBER MOSAIC VIRUS; GB VIRUS C/HEPATITIS G VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; SARS CORONAVIRUS; SARS COV;

EID: 20444420545     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biologicals.2005.01.003     Document Type: Article

References (25)

1. L. Biesert, T. Gärtner, S. Lemon, B. Horowitz, S. Suhartono, and L. Wang Octaplas: eine virusinaktivierte Alternative zu gefrorenem Frischplasma Infusther Transfusmed 22 Suppl. 1 1995 2 4
2. L. Biesert Virus validation studies of immunoglobulin preparations Clin Exp Rheumatol 14 Suppl. 15 1996 47 52
3. Bundesgesundheitsamt und Paul-Ehrlich-Institut, Bundesamt für Sera und Impfstoffe. Bekanntmachung über die Zulassung von Arzneimitteln. Anforderungen an Virusvalidierungsstudien zum Nachweis der Virussicherheit von Arzneimitteln aus menschlichem Blut oder Plasma vom 20. Dezember 1993/21. Januar 1994; BAnz. vom 04.05.1995;4742-4.
4. Centers for Disease Control and Prevention (CDC) Update: outbreak of severe acute respiratory syndrome - worldwide, 2003 MMWR Morb Mortal Wkly Rep 52 2003 241 246 248
5. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on plasma derived medicinal products. The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit 1996; CPMP/BWP/269/95; 1-17.
6. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on virus validation studies; the design, contribution and interpretation of studies validating the inactivation and removal of viruses. The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit 1996; CPMP/BWP/268/95; 1-13.
7. C. Drosten, S. Günther, W. Preiser, S. van der Werf, H.R. Brodt, and S. Becker Identification of a novel coronavirus in patients with severe acute respiratory syndrome N Engl J Med 348 2003 1967 1976
8. C. Drosten, W. Preiser, S. Günther, H. Schmitz, and H.W. Doerr Severe acute respiratory syndrome: identification of the etiological agent Trends Mol Med 9 2003 325 327
9. B. Horowitz, R. Bonomo, A.M. Prince, N.C. Sing, B. Brotman, and R.W. Shulman Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma Blood 79 1992 826 831
10. B. Horowitz, A. Lazo, and H. Grossberg Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma Vox Sang 74 Suppl. 1 1998 203
11. B. Horowitz, M.E. Wiebe, A. Lippin, and M.H. Stryker Inactivation of viruses in labile bIood derivatives. 1. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combination Transfusion 25 1985 516 522
12. G. Kärber Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 152 1931 380
13. T. Kreil, A. Berting, O. Kistner, and J. Kindermann West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data Transfusion 43 2003 1023 1028
14. W. Liang, Z. Zhu, J. Guo, Z. Liu, X. He, and W. Zhou for the Beijing Joint SARS Expert Group (2003) Severe acute respiratory syndrome, Beijing, 2003 Emerg Infect Dis 10 2004 25 31
15. M.A. Marra, S.J. Jones, C.R. Astell, R.A. Holt, A. Brooks-Wilson, and Y.S. Butterfield The genome sequence of the SARS-associated coronavirus Science 300 2003 1399 1404
16. J.S. Peiris, C.M. Chu, V.C. Cheng, K.S. Chan, I.F. Hung, and L.L. Poon Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study Lancet 361 2003 1767 1772
17. M.P.J. Piet, S. Chin, A.M. Prince, B. Brotman, A.M. Cundell, and B. Horowitz The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation Transfusion 30 1990 591 598
18. H.F. Rabenau, J. Cinatl, B. Morgenstern, G. Bauer, W. Preiser, and H.W. Doerr Stability and inactivation of SARS-associated Coronavirus (SARS-CoV) J Med Microbiol Immunol 194 2005 1 6
19. Rabenau HF, Kampf G, Bauer G, Doerr HW. Inactivation of SARS-coronavirus (SARS-CoV). Hospital Infection 2005, in press.
20. P.A. Rota, M.S. Oberste, S.S. Monroe, W.A. Nix, R. Campagnoli, and J.P. Icenogle Characterization of a novel coronavirus associated with severe acute respiratory syndrome Science 300 2003 1394 1399
21. M. Schmidt, V. Brixner, B. Ruster, M.K. Hourfar, C. Drosten, and W. Preiser NAT screening of blood donors for severe acute respiratory syndrome coronavirus can potentially prevent transfusion associated transmissions Transfusion 44 2004 470 475
22. W.H. Seto, D. Tsang, R.W. Yung, T.Y. Ching, T.K. Ng, and M. Ho Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS) Lancet 361 2003 1519 1520
23. C. Spearman The method of "right or wrong cases" (constant stimuli) without Gauss's formulae Br J Psychol 2 1908 227
24. WHO environmental health team. Report on Amoy Gardens. World Health Organization Regional Office for the Western Pacific; 2003. Available at: 〈http://www.info.gov.hk/info/ap/who-amoye.pdf〉 [accessed on 2 December 2003].
25. J. Wu, F. Xu, W. Zhou, D.R. Feikin, C.Y. Lin, and X. He Risk factors for SARS among persons without known contact with SARS patients, Beijing, China Emerg Infect Dis 10 2004 210 216